Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ohali, A.
Right arrow Articles by Zaizov, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ohali, A.
Right arrow Articles by Zaizov, R.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?
Journal of Clinical Oncology, Vol 21, Issue 20 (October), 2003: 3836-3843
© 2003 American Society for Clinical Oncology

Association Between Telomerase Activity and Outcome in Patients With Nonmetastatic Ewing Family of Tumors

A. Ohali, S. Avigad, I.J. Cohen, I. Meller, Y. Kollender, J. Issakov, I. Gelernter, Y. Goshen, I. Yaniv, R. Zaizov

From the Department of Molecular Oncology, Felsenstein Medical Research Center, and the Department of Pediatric Hematology/Oncology, Schneider Children’s Medical Center of Israel, Petah Tikva; and Sourasky Medical Center, Sackler Faculty of Medicine, and Statistical Laboratory, School of Mathematics, Tel Aviv University, Tel Aviv, Israel.

Address reprint requests to Smadar Avigad, PhD, Molecular Oncology, Felsenstein Medical Research Center, Rabin Medical Campus, Petah Tikva 49100, Israel; e-mail: savigad{at}post.tau.ac.il.

Purpose: Telomerase is considered a molecular marker for malignancy. The aim of this study was to determine telomerase activity (TA) as a prognostic factor at diagnosis and as a marker for minimal residual disease during therapy and follow-up in nonmetastatic Ewing family of tumors (EFT).

Patients and Methods: Primary tumor specimens and 97 peripheral blood (PBL) samples from 31 EFT patients were analyzed for TA by the Telomeric Repeat Amplification Protocol (TRAP assay). The telomerase catalytic subunit (human telomerase reverse transcriptase [hTERT]) gene expression was evaluated by quantitative reverse transcriptase polymerase chain reaction (RT-PCR) and telomere length was determined by Southern blotting. The presence of the EFT chimeric transcripts was analyzed by RT-PCR. Correlations with progression-free survival were evaluated.

Results: At diagnosis, TA in primary tumors did not correlate with outcome. During therapy and follow-up, highly significant correlation was observed between high TA in PBL samples and adverse prognosis (P < .0001). None of the patients harboring low TA progressed, with a long follow-up (median, 60 months) and a progression-free survival (PFS) of 100%. In nine patients, high TA actually could predict relapse, long before overt clinical relapse. The group of patients with high TA and positive RT-PCR had the most adverse outcome; PFS of 20% (P = .0025). TA was found to be a better prognostic factor than RT-PCR and histopathologic response at surgery.

Conclusion: The results suggest that TA is a significant prognostic variable, superior to the established clinical prognostic parameters during therapy and tumor surveillance. It could be used in combination with RT-PCR for a new risk classification.

This work was supported by the Josefina Maus and Gabriela Cesarman Maus Chair for Pediatric Hematology Oncology (R.Z.).

This work was performed in partial fulfillment of the requirements for the PhD degree of Anat Ohali, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
Anticancer ResHome page
T. MATSUO, S. SHIMOSE, T. KUBO, J. FUJIMORI, Y. YASUNAGA, and M. OCHI
Telomeres and Telomerase in Sarcomas
Anticancer Res, October 1, 2009; 29(10): 3833 - 3836.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
S. Avigad, I. Naumov, A. Ohali, M. Jeison, G. H. Berco, J. Mardoukh, B. Stark, S. Ash, I. J. Cohen, I. Meller, et al.
Short Telomeres: A Novel Potential Predictor of Relapse in Ewing Sarcoma
Clin. Cancer Res., October 1, 2007; 13(19): 5777 - 5783.
[Abstract] [Full Text] [PDF]


Home page
J. Cell Sci.Home page
M. K. Lee, M. P. Hande, and K. Sabapathy
Ectopic mTERT expression in mouse embryonic stem cells does not affect differentiation but confers resistance to differentiation- and stress-induced p53-dependent apoptosis
J. Cell Sci., February 15, 2005; 118(4): 819 - 829.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
R. P. Sanders, R. Drissi, C. A. Billups, N. C. Daw, M. B. Valentine, and J. S. Dome
Telomerase Expression Predicts Unfavorable Outcome in Osteosarcoma
J. Clin. Oncol., September 15, 2004; 22(18): 3790 - 3797.
[Abstract] [Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 2003 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online